Please assess the completion status of the following clinical trial:

Trial Title: S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian epithelial carcinoma~  * Stage III or IV disease at time of initial staging laparotomy~* Primary peritoneal and mixed Mullerian tumors allowed~* No borderline ovarian tumors~* Disease progression or recurrence after a progression-free and platinum-free interval of 6-24 months after completion of first-line platinum-based chemotherapy (either single agent or combination therapy)~* Disease progression or recurrence based solely on CA 125 elevation allowed, provided that one of the following is true:~  * Prior baseline CA 125 greater than 35 U/mL and subsequent normalization of no greater than 35 U/mL must have CA 125 greater than 2 times upper limit of normal (ULN) on 2 occasions at least 1 week apart~ * Prior baseline CA 125 greater than 35 U/mL that never normalized must have CA 125 greater than 2 times the nadir value on 2 occasions at least 1 week apart~ * Prior normal baseline CA 125 (no greater than 35 U/mL) must show CA 125 greater than 2 times ULN on 2 occasions at least 1 week apart~* No known brain metastases~PATIENT CHARACTERISTICS:~Age~* Not specified~Performance status~* Zubrod 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* SGOT and/or SGPT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~* Bilirubin no greater than ULN~Renal~* Creatinine no greater than 1.9 mg/dL~Cardiovascular~* No New York Heart Association class II-IV cardiac disease~* No clinical evidence of congestive heart failure~* Ejection fraction greater than 50% by MUGA or 2-dimensional echocardiogram~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or incidental carcinoid cancer~* No evidence of active or uncontrolled infection~* No severe gastrointestinal symptoms (i.e., partial obstruction) and/or gastrointestinal bleeding or diarrhea~* No greater than grade 1 preexisting sensory neuropathy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 28 days since prior biologic consolidation therapy~* No concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* At least 28 days since prior non-platinum-containing consolidation chemotherapy~* No prior pegylated doxorubicin HCl liposome~* No prior cumulative anthracycline (e.g., doxorubicin, daunorubicin, epirubicin) dose in excess of 240 mg/m\^2~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent hormonal therapy~Radiotherapy~* No prior abdominopelvic irradiation~* No concurrent radiotherapy~Surgery~* See Disease Characteristics~* At least 28 days since prior surgical debulking for disease progression or recurrence and recovered~* No concurrent surgery~Other~* No other prior treatment during the 6-24 month progression-free and platinum-free interval except up to 12 courses of consolidation therapy~* No other concurrent anticancer therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- carboplatin and doxorubicin (Type: EXPERIMENTAL): carboplatin and liposomal doxorubicin given q 4 weeks
- carboplatin (Type: ACTIVE_COMPARATOR): carboplatin alone

Based on this trial design, predict the completion outcome and termination type (if applicable).